Bay Area Biotech Forum
Biotech's business model is shifting. As venture funding and basic science funding from the government has slowed, patient-focused disease foundations are investing more in innovative drug development.
*What is the impact of these broad trends on the Bay Area's long-standing biotech industry dominance?
*Can the Bay Area retain its biotech magic to regenerate waves of life sciences companies?
Join long-time Emeryville Chamber of Commerce partner the San Francisco Business Times for this lively panel discussion with leaders of the biotech industry and presentations from three young life sciences companies that could be the Next Big Thing in biotech.
Panel One: Biotech's Next Move
*Craig Muir, Partner, Third Rock Ventures
*Glenn Oclassen, President & CEO, Transcept Pharmaceuticals
*Lissa Goldenstein, President & CEO, Auxogyn
*Gideon Bollag, Senior Vice President for Research, Plexxikon Inc.
Panel Two: The Next Big Thing
*Tom Chalberg, President & CEO, Avalanche Biotechnologies
*Minnie Sarwal, Co-founder, Organ-i
*Andrew Gengos, President & CEO, Neuraltus Pharmaceuticals
Moderated by Ron Leuty, biotech reporter, San Francisco Business Times
Opening remarks by Christie Smith, Principal, West Region Life Sciences Leader, Women's Initiative Leader, Diversity & Inclusion Leader, Deloitte Consulting LL
For more info, contact Jacquie Bischoff at 415-288-4972 or firstname.lastname@example.org
When: Thursday, June 14, 2012, 7:30 a.m.- 10:00 a.m.
Where: Hilton San Francisco Union Square 333 O'Farrell Street, San Francisco
Cost: Starting at $70
Suggested Dress: Business Attire